Last reviewed · How we verify
NCT05136300: PROMISE
Pulmonary Rehabilitation After Minimal Invasive Surgery in Lung Cancer
NA trial testing Pulmonary rehabilitation in Lung Cancer in 100 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Isala |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 May 2019 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 July 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Pulmonary rehabilitation
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Surgery — all drugs for Surgery →
Sponsor
Isala — full company profile →
Who can join
Adults 18 to 80, any sex, with Lung Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Morbidity in the post-operative phase of pulmonary surgery is characterised by impairment due to pain, dyspnoea and loss of exercise tolerance. We demonstrated previously that rehabilitation after thoracotomy is limited due to pain. Since minimal invasive surgery is the new standard in lung cancer, resulting in a reduction of postoperative pain, we believe there are new possibilities for post-operative integrated multidisciplinary rehabilitation in lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05136300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pulmonary rehabilitation
Trials testing the same drug.
- NCT07088185 — Pulmonary Outcomes on Patients With Lung Fibrosis · NA · active not recruiting
- NCT06522724 — Education Impact on Rehabilitation of Hospitalized Patients With Pneumonia and COVID-19 · NA · completed
- NCT06366113 — Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD) · NA · recruiting
- NCT06028711 — Education Impact on Rehabilitation of Hospitalized Patients with Chronic Obstructive Pulmonary Disease. · NA · completed
- NCT06051136 — Early Versus Delayed Rehabilitation Intervention in Patients With Lung Cancer · NA · active not recruiting
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Isala trials
Trials by the same sponsor.
- NCT06342843 — Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH) · NA · recruiting
- NCT05682027 — Ultrasound as Diagnostic Tool in Diaphragm Dysfunction · completed
- NCT05860686 — Does Post-operative Rinsing With a Monoject Syringe Result in as Much Post-operative Pain After Surgical Removal of Lowe · NA · unknown
- NCT05180955 — The Role of Clamping Before Removal of a Pneumothorax Drain Connected to a Digital Drainage System. · NA · completed
- NCT05420974 — NIR Arthroscopic Fluorescence Angiography of Menisci · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05136300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isala
- Last refreshed: 3 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05136300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing